Advanced Proteome Therapeutics Corporation is a biotechnology company. The Company is engaged in the development of anti-cancer therapeutics that exploit the properties of a natural human protein. The Company, through its subsidiary, Advanced Proteome Therapeutics Inc. (APTI), develops and commercializes a new technology platform that is intended for the chemical modification of protein therapeutics. The Foundation Trinity Technology is combining anti-cancer therapies in a single agent for targeted delivery to tumors. It is engaged in targeted therapy, immunotherapy and combination therapy. The Company's technology is applicable to the areas of therapeutics and diagnostics, protein drugs and personalized medicine, and is being applied to cancer therapeutics. It is focusing on enabling technology, designed to link antibodies to drugs or toxins, to produce pure and homogeneous antibody-drug conjugates (ADC).